Nurix Therapeutics, Inc. NRIX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s restricted cash?
- Nurix Therapeutics, Inc. (NRIX) reported restricted cash of $968K in Q4 2025.
- How has Nurix Therapeutics, Inc.'s restricted cash changed year-over-year?
- Nurix Therapeutics, Inc.'s restricted cash increased by 7.4% year-over-year, from $901K to $968K.
- What is the long-term trend for Nurix Therapeutics, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Nurix Therapeutics, Inc.'s restricted cash has grown at a 41.6% compound annual growth rate (CAGR), from $170K to $968K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.